CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement

Bulletin Express07-03

CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 30 June 2026, showing no movements in either authorised or issued share capital.

Authorised Share Capital • Total authorised capital remained at 247.04 million shares, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.

Issued Share Capital • Issued H shares: 132.67 million. • Issued A shares: 114.37 million. • No new shares were issued, repurchased or cancelled during the month. • Treasury share balance stayed at zero for both share classes.

Public Float • The company confirmed compliance with the 5 % minimum public-float requirement for its H-share class under HKEX Main Board Rule 13.32B.

Equity Incentive Plans • H-Share Core Management Option Scheme (adopted 23 Oct 2025): 860,000 options outstanding; no exercises in June. • A-Share Restricted Stock Incentive Scheme (adopted 23 Oct 2025): 2.05 million restricted shares remain available for future issuance; no grants, vesting or cancellations occurred in June.

Capital Structure Summary (as at 30 June 2026) • Total issued shares: 247.04 million. • Treasury shares: none. • Par value per share: RMB 1.

The filing, signed by Joint Company Secretary Jin Cui on 3 July 2026, indicates a period of capital stability with sufficient liquidity in the market for the Hong Kong-listed H shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185978580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185978580","market":"hk","top_or_hot":-1,"title":"CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 30 June 2026, showing no movements in either authorised or issued share capital.</p>\n<p>Authorised Share Capital  \n• Total authorised capital remained at 247.04 million shares, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.</p>\n<p>Issued Share Capital  \n• Issued H shares: 132.67 million.  \n• Issued A shares: 114.37 million.  \n• No new shares were issued, repurchased or cancelled during the month.  \n• Treasury share balance stayed at zero for both share classes.</p>\n<p>Public Float  \n• The company confirmed compliance with the 5 % minimum public-float requirement for its H-share class under HKEX Main Board Rule 13.32B.</p>\n<p>Equity Incentive Plans  \n• H-Share Core Management Option Scheme (adopted 23 Oct 2025): 860,000 options outstanding; no exercises in June.  \n• A-Share Restricted Stock Incentive Scheme (adopted 23 Oct 2025): 2.05 million restricted shares remain available for future issuance; no grants, vesting or cancellations occurred in June.</p>\n<p>Capital Structure Summary (as at 30 June 2026)  \n• Total issued shares: 247.04 million.  \n• Treasury shares: none.  \n• Par value per share: RMB 1.</p>\n<p>The filing, signed by Joint Company Secretary Jin Cui on 3 July 2026, indicates a period of capital stability with sufficient liquidity in the market for the Hong Kong-listed H shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 30 June 2026, showing no movements in either authorised or issued share capital.</p>\n<p>Authorised Share Capital  \n• Total authorised capital remained at 247.04 million shares, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.</p>\n<p>Issued Share Capital  \n• Issued H shares: 132.67 million.  \n• Issued A shares: 114.37 million.  \n• No new shares were issued, repurchased or cancelled during the month.  \n• Treasury share balance stayed at zero for both share classes.</p>\n<p>Public Float  \n• The company confirmed compliance with the 5 % minimum public-float requirement for its H-share class under HKEX Main Board Rule 13.32B.</p>\n<p>Equity Incentive Plans  \n• H-Share Core Management Option Scheme (adopted 23 Oct 2025): 860,000 options outstanding; no exercises in June.  \n• A-Share Restricted Stock Incentive Scheme (adopted 23 Oct 2025): 2.05 million restricted shares remain available for future issuance; no grants, vesting or cancellations occurred in June.</p>\n<p>Capital Structure Summary (as at 30 June 2026)  \n• Total issued shares: 247.04 million.  \n• Treasury shares: none.  \n• Par value per share: RMB 1.</p>\n<p>The filing, signed by Joint Company Secretary Jin Cui on 3 July 2026, indicates a period of capital stability with sufficient liquidity in the market for the Hong Kong-listed H shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1185978580","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185978580","pubTimestamp":1783068163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 30 June 2026, showing no movements in either authorised or issued share capital. Authorised Share Capital   • Total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物预计2026年6月股本稳定；公众持股量符合港交所规定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 30 June 2026, showing no movements in either authorised or issued share capital.\nAuthorised Share Capital  \n• Total authorised capital remained at 247.04 million shares, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.\nIssued Share Capital  \n• Issued H shares: 132.67 million.  \n• Issued A shares: 114.37 million.  \n• No new shares were issued, repurchased or cancelled during the month.  \n• Treasury share balance stayed at zero for both share classes.\nPublic Float  \n• The company confirmed compliance with the 5 % minimum public-float requirement for its H-share class under HKEX Main Board Rule 13.32B.\nEquity Incentive Plans  \n• H-Share Core Management Option Scheme (adopted 23 Oct 2025): 860,000 options outstanding; no exercises in June.  \n• A-Share Restricted Stock Incentive Scheme (adopted 23 Oct 2025): 2.05 million restricted shares remain available for future issuance; no grants, vesting or cancellations occurred in June.\nCapital Structure Summary (as at 30 June 2026)  \n• Total issued shares: 247.04 million.  \n• Treasury shares: none.  \n• Par value per share: RMB 1.\nThe filing, signed by Joint Company Secretary Jin Cui on 3 July 2026, indicates a period of capital stability with sufficient liquidity in the market for the Hong Kong-listed H shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185978580","isCrawlerRequest":true}